Sale!

CDKN2A Gene Pancreatic Cancer Melanoma Syndrome Familial NGS Genetic DNA Test

Original price was: $700.Current price is: $500.

-29%

The CDKN2A Gene Pancreatic Cancer Melanoma Syndrome Familial NGS Genetic DNA Test is a comprehensive genetic screening that identifies mutations in the CDKN2A gene, which significantly increases the risk of developing pancreatic cancer and melanoma. This advanced next-generation sequencing test provides crucial information for individuals with family histories of these cancers, enabling proactive health management and early intervention strategies. The test costs $500 USD and includes professional genetic counseling to help interpret results and develop personalized surveillance plans. By detecting inherited cancer predispositions, patients can work with their healthcare providers to implement targeted screening protocols and preventive measures, potentially saving lives through early detection and intervention.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

CDKN2A Gene Pancreatic Cancer Melanoma Syndrome Familial NGS Genetic DNA Test

Comprehensive Genetic Assessment for Hereditary Cancer Risk

The CDKN2A Gene Pancreatic Cancer Melanoma Syndrome Familial NGS Genetic DNA Test represents a breakthrough in personalized cancer risk assessment. This sophisticated genetic analysis utilizes next-generation sequencing technology to identify mutations in the CDKN2A gene, which plays a critical role in regulating cell division and preventing uncontrolled cell growth. Understanding your genetic predisposition to pancreatic cancer and melanoma can be life-saving, enabling proactive health management and targeted surveillance strategies.

What Does This Test Measure and Detect?

This comprehensive genetic test specifically analyzes the CDKN2A gene for pathogenic variants that are associated with:

  • Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome
  • Hereditary pancreatic cancer predisposition
  • Increased risk of developing multiple melanomas
  • Genetic mutations passed through family generations
  • Specific CDKN2A gene alterations affecting tumor suppression

The test employs advanced NGS technology to provide high-resolution analysis of the entire CDKN2A gene, ensuring comprehensive detection of both common and rare mutations that may increase cancer susceptibility.

Who Should Consider This Genetic Test?

This test is particularly recommended for individuals who meet any of the following criteria:

  • Personal history of pancreatic cancer diagnosed at any age
  • Family history of pancreatic cancer in one or more first-degree relatives
  • Personal diagnosis of melanoma, especially if diagnosed before age 50
  • Multiple primary melanomas in the same individual
  • Family history of both pancreatic cancer and melanoma
  • Presence of numerous atypical moles (dysplastic nevi)
  • Known CDKN2A mutation in the family
  • Ashkenazi Jewish ancestry with family cancer history

Significant Benefits of Genetic Testing

Undergoing CDKN2A genetic testing provides numerous advantages for health management:

  • Early Risk Identification: Detect genetic predispositions before cancer develops
  • Personalized Surveillance: Implement targeted screening protocols based on genetic risk
  • Family Planning: Make informed decisions about genetic inheritance
  • Preventive Strategies: Develop proactive health management plans
  • Peace of Mind: Reduce uncertainty about inherited cancer risks
  • Family Member Screening: Identify at-risk relatives who may benefit from testing

Understanding Your Test Results

Your genetic test results will fall into one of several categories, each with specific implications:

  • Positive Result: A pathogenic mutation was detected, indicating increased cancer risk. This result enables implementation of enhanced surveillance and preventive measures.
  • Negative Result: No known pathogenic mutations were identified. However, cancer risk may still exist due to other genetic or environmental factors.
  • Variant of Uncertain Significance (VUS): A genetic change was found, but its clinical significance is unknown. Regular follow-up is recommended as research evolves.
  • No Mutation Detected: No CDKN2A mutations were found in individuals from families with known mutations, significantly reducing personal cancer risk.

All results are accompanied by comprehensive genetic counseling to ensure proper interpretation and development of personalized management plans.

Test Pricing and Availability

Test Feature Details
Test Name CDKN2A Gene Pancreatic Cancer Melanoma Syndrome Familial NGS Genetic DNA Test
Discount Price $500 USD
Regular Price $700 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology

Nationwide Testing Availability

We have established testing facilities across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Miami, Seattle, Boston, and Phoenix. Our network of certified genetic counselors and healthcare professionals ensures accessible, high-quality genetic testing services nationwide.

Take Control of Your Genetic Health Today

Don’t wait to understand your genetic cancer risks. Early detection through comprehensive genetic testing can provide the knowledge needed to implement effective prevention and surveillance strategies. Our team of genetic specialists is ready to guide you through the testing process and help interpret your results within the context of your personal and family medical history.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic counseling session and book your CDKN2A genetic test. Take the first step toward proactive cancer risk management and personalized health planning.